Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

For the first time in a decade, U.S. obesity rates have begun to decline, raising hopes that the nation may be turning a ...

New drugs from public and private companies are expected to saturate the obesity drug market. Novo Nordisk and Eli Lilly are currently dominating the weight loss drug market, but biopharmaceutical ...

Other analysts are more cautious, however, predicting peaks sales of $1 billion or lower and pointing to lacklustre take-up of other new obesity drugs such as Eisai and Arena's Belviq (lorcaserin ...

One option is to double down on the obesity market, by buying promising new drugs that may complement or even replace the GLP-1 products. One target could be Zealand Pharma (ZELA.CO), opens new ...

(Those are slightly higher shares than the estimate from the Center s for Disease Control and Prevention, which says around 40% of U.S. adults had obesity from 2021 ... the new drugs' true impact.

Brownstein and his team noted that women and adults aged 66 to 75 saw the largest decreases in obesity. People living in the South, where they had the highest dispensing rate of weight loss drugs ...

in New York City. Gary Hershorn/Getty Images Last year, poison control centers across the country reported spikes in calls related to overdoses of anti-obesity medications. Authorities attributed ...

U.S. obesity declined slightly in 2023, new data showed, perhaps marking the first time in over a decade there’s been a decline. The dip comes amid the booming popularity of weight loss drugs ...